1. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 The Diabetic Patient and Drug Eluting Stents

2. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 Integrity ™ DES Resolute Integrity ™ DES Established Components Integrity™ cobalt alloy stentIntegrity™ cobalt alloy stent MicroTrac™ delivery systemMicroTrac™ delivery system Zotarolimus antiproliferative drugZotarolimus antiproliferative drug Unique Polymer Technology BioLinx™ polymer is a unique blend of three polymers to control drug release, support biocompatibility and enhance elution rateBioLinx™ polymer is a unique blend of three polymers to control drug release, support biocompatibility and enhance elution rate Drug-release kinetics: complete elution by 180 daysDrug-release kinetics: complete elution by 180 days 100 80 60 40 20 0 Zotarolimus Release (%) 050100150200 Days % eluted System Components Udipi K, et al. EuroIntervention. 2007; 3:137-9 Meredith IT, et al. J Am Coll Cardiol Intv. 2009; 2:977-85 Meredith IT, et al. EuroIntervention. 2007; 3:50-53

3. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012RESOLUTE139 RESOLUTE AC 1140 RESOLUTE Int 2349 RESOLUTE US 1402 RESOLUTE Japan 100 5130 Resolute™ DES population Matched cohort diabetic population N = 878 (standard risk) Matched cohort is all enrolled diabetic subjects excluding subjects with bifurcation, saphenous vein graft (SVG), ISR, AMI (≤72 hours), left ventricular ejection fraction (LVEF) 27 mm, ≥2 lesions per vessel, lesion with thrombus, or lesion with total occlusion. Diabetic Patient Populations RESOLUTE Pooled Diabetic Analysis Total diabetic patient population N = 1535 Standard risk patient cohort pre-specified for FDA indication

4. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 RESOLUTE Pooled Diabetic Analysis Resolute™ DES matched cohort was compared against prespecified performance goal based on DES meta-analysis. Prespecified analysis designed with FDA for indication to treat patients with diabetes. Resolute™ DES matched cohort was compared against prespecified performance goal based on DES meta-analysis. FDA Approved Indication Performance Goal* Resolute DES † Target vessel failure (TVF) is defined as cardiac death, target vessel myocardial infarction, and clinically driven target vessel revascularization (TVR) * Performance goal based on DES trials meta-analysis: DIABETES, RAVEL DM, SIRIUS DM, TAXUS IV, SCORPIUS, ENDEAVOR Pooled DM † RESOLUTE matched cohort diabetes pooled analysis (N = 878). Target Vessel Failure at 12 Months (powered endpoint) Target Vessel Failure at 12 Months (powered endpoint) 14.5 7.8 P = 0.001 Events (%)

5. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 Why is Medtronic interested in Diabetes as a high risk group for patients undergoing PCI?

6. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 The Prevalence of Diabetes Keeps Increasing… Diabetes currently affects 25.8 million people in the United States 2 1.Maps of Diabetes and Obesity in 1994, 2000, and 2009. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/diabetes/statistics/slides/maps_diabetesobesity94.pdf. Accessed 10/13/11. 2.National Diabetes Statistics, 2011. National Diabetes Information Clearinghouse Web site. http://www.diabetes.niddk.nih.gov/dm/pubs/statistics/#fast. Accessed 11/28/11. 1994 1 2000 1 2009 1 No data <4.5% 4.5%-5.9% 6.0%-7.4% 7.5%-8.9% ≥9.0%

7. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 …and Is Estimated to Still Be on the Rise Year US Population, % By 2020, it is projected that 39 million people will have diabetes and 96 million people will have prediabetes in the United States By 2020, it is projected that 39 million people will have diabetes and 96 million people will have prediabetes in the United States The United States of diabetes: challenges and opportunities in the decade ahead. http://www.unitedhealthgroup.com/hrm/UNH_ WorkingPaper5.pdf. UnitedHealth Center for Health Reform & Modernization working paper 5. Published November 2010. Accessed 11/28/11.

8. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 The Risk of Adverse Events Increases in Patients With Both CVD and Diabetes Circulatory disorders associated with diabetes include coronary heart disease, stroke, peripheral arterial disease, cardiomyopathy, and congestive heart failure 1Circulatory disorders associated with diabetes include coronary heart disease, stroke, peripheral arterial disease, cardiomyopathy, and congestive heart failure 1 –Even in the absence of CVD, both the ADA and the AHA identify diabetes as a high risk condition for macrovascular CVD 2,3 CVD is a major complication of diabetes and the leading cause of early death 4CVD is a major complication of diabetes and the leading cause of early death 4 –About 65% of people with diabetes die from heart disease or stroke Adults with diabetes are 2-4 times more likely to have heart disease or a stroke than those without diabetes 4Adults with diabetes are 2-4 times more likely to have heart disease or a stroke than those without diabetes 4 High blood glucose in adults with diabetes increases the risk of myocardial infarction, angina, stroke, and coronary artery disease 5High blood glucose in adults with diabetes increases the risk of myocardial infarction, angina, stroke, and coronary artery disease 5 People with type 2 diabetes also have high rates of hypertension, high cholesterol, and obesity 6People with type 2 diabetes also have high rates of hypertension, high cholesterol, and obesity 6 ADA=American Diabetes Association; AHA=American Heart Association; CVD=cardiovascular disease. 1 Buse J, et al. Diabetes Care. 2007;30:162-172. 2 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001;285:2486-2497. 3 American Diabetes Association. Diabetes Care. 2011;(suppl 1):S11-S61. 4 The Link Between Diabetes and Cardiovascular Disease. National Diabetes Education Program Web site. http://ndep.nih.gov/media/CVD_FactSheet.pdf. Accessed 11/28/11. 5 Nathan D, et al. N Engl J Med. 2005;353:2643-2653. 6 National Diabetes Statistics, 2011. National Diabetes Information Clearinghouse Web site. http://www.diabetes.niddk.nih.gov/dm/pubs/statistics/#fast. Accessed 11/28/11.

9. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 CVD and CHD Mortality Rates Are Significantly Higher in Adults With Diabetes N = 6255 Mean follow-up, 13.3 years N = 6255 Mean follow-up, 13.3 years Mortality Rates in US Adults With vs Without Diabetes and/or Preexisting CVD Deaths per 1000 Person-Years a a Adjusted by age and gender. CHD = coronary heart disease; CVD = cardiovascular disease. Adapted from Malik S, et al. Circulation. 2004;110:1245-1250.

10. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 Complications of Diabetes and CVD Account for Almost Half of Top Diagnoses for Health Expenses The 16 Leading Diagnoses for Direct Health Expenditures: United States, 2007 Billions of Dollars Unrelated to CVD/diabetes Related to CVD/diabetes COPD = chronic obstructive pulmonary disease; CVD = cardiovascular disease. Roger V, et al. Circulation. 2011;123:e18-e209.

11. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 ~30% of PCIs are in Patients with Diabetes PCI=percutaneous coronary intervention. Aronson D and Edelman ER. (2010) Revascularization for Coronary Artery Disease in Diabetes Mellitus: Angioplasty, Stents and Coronary Artery Bypass Grafting. Rev. Endocr. Metab. Disord. 11:75-86

12. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 Patients with Diabetes Have Poorer Outcomes Post PCI Compared with patients without diabetes, patients with diabetes experience: Twice the early mortality associated with acute coronary syndromeTwice the early mortality associated with acute coronary syndrome Higher rate of reinfarctionHigher rate of reinfarction Higher likelihood of myocardial infarction in first year post PCIHigher likelihood of myocardial infarction in first year post PCI More procedural complicationsMore procedural complications Longer ICU and hospital staysLonger ICU and hospital stays Increased interactions with hypoglycemic medicationsIncreased interactions with hypoglycemic medications Higher rates of restenosis, target lesion revascularization, and target vessel revascularizationHigher rates of restenosis, target lesion revascularization, and target vessel revascularization ICU=intensive care unit; PCI=percutaneous coronary intervention. Nesto R, et al. Presented at TCT 2003. Rutter MK, Nesto RW. Heart. 2010 Sep;96(18):1436-40.Coronary revascularisation in the patient with diabetes: balancing risk and benefit.

13. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 What Mechanisms Underlie Poorer Outcomes in Diabetics after PCI? Platelet and endothelial dysfunction resulting in accelerated atherosclerosis and plaque instabilityPlatelet and endothelial dysfunction resulting in accelerated atherosclerosis and plaque instability Plaques from diabetic patients removed by coronary atherectomy have greater lipid deposits and numbers of macrophagesPlaques from diabetic patients removed by coronary atherectomy have greater lipid deposits and numbers of macrophages Endothelial dysfunction is thought to induce negative arterial remodeling in response to atherosclerosis resulting in a decrease in luminal sizeEndothelial dysfunction is thought to induce negative arterial remodeling in response to atherosclerosis resulting in a decrease in luminal size Roffi, M et al. Current concepts on revascularization in diabetic patients. Eur Heart Journal. 2011. 32:2748-2757. Moreno PR et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 2000 Oct 31;102(18):2180-4.

14. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 Questions How often is the diabetic status of a patient known prior to PCI?How often is the diabetic status of a patient known prior to PCI? How often do you know if the patient is NIDDM or IDDM?How often do you know if the patient is NIDDM or IDDM? Would this affect your treatment strategy?Would this affect your treatment strategy? (N)IDDM = (non) Insulin-Dependent Diabetes Mellitus

15. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 How are Drug Eluting Stents Performing in Diabetic Patients?

16. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 DES Results in More Overt Benefits vs BMS in Patients Without Diabetes Patients, % P < 0.001 P = 0.31 P < 0.001 P = 0.22 P = 0.13 Patients, % P < 0.001 Outcomes at 4 Years in Patients Without Diabetes (n = 2751) Outcomes at 4 Years in Patients With Diabetes (n = 1826) BMS=bare-metal stent; DES=drug-eluting stent; MACE=major adverse cardiac event; MI=myocardial infarction; TVR=target vessel revascularization. All stents implanted between 4/2004-12/2008. Minha S, et al. Catheter Cardiovasc Interv. 2011;78:710-717.

17. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 TAXUS IV Diabetic Analysis: Evaluating the Safety of TAXUS ® Express ® vs BMS – Study Design The primary endpoint was TVR at 9 months; secondary endpoints included TLR, non-TLR TVR, MI, and major adverse cardiac events (MI, TVR, and stent thrombosis)The primary endpoint was TVR at 9 months; secondary endpoints included TLR, non-TLR TVR, MI, and major adverse cardiac events (MI, TVR, and stent thrombosis) Aspirin 325 mg mandatory; clopidogrel 75 mg daily for ≥6 monthsAspirin 325 mg mandatory; clopidogrel 75 mg daily for ≥6 months Clinical follow-up only: 1, 4, 9 months and yearly for total of 5 years 1326 patients enrolled at 73 US sites; single de novo lesion coverable by 1 stent; RVD, >2.5-3.75 mm; lesion length, 10-28 mm 1326 patients enrolled at 73 US sites; single de novo lesion coverable by 1 stent; RVD, >2.5-3.75 mm; lesion length, 10-28 mm Randomized 1:1 TAXUS Express ™ DES vs identical uncoated BMS Stratified by diabetes and vessel diameter Randomized 1:1 TAXUS Express ™ DES vs identical uncoated BMS Stratified by diabetes and vessel diameter BMS (n = 652) TAXUS (n = 662) Diabetes (n = 152) Diabetes No diabetes (n = 510) No diabetes (n = 510) Diabetes (n = 163) Diabetes No diabetes (n = 489) No diabetes (n = 489) BMS = bare-metal stent; MI = myocardial infarction; RVD = reference vessel diameter; TLR = target lesion revascularization; TVR = target vessel revascularization. Ellis S, et al. JACC Cardiovasc Interv. 2009;2:1248-1259.

18. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 TAXUS IV Diabetic Analysis: Treatment With TAXUS ® DES vs BMS Does Not Result in Any Significant Benefit Except for TLR in Patients With Diabetes Rates of All Death, MI, ARC ST Definite/Probable, and TLR Through 5 Years in Patients With vs Without Diabetes Patients, % ARC = Academic Research Consortium; BMS = bare-metal stent; MI = myocardial infarction; ST = stent thrombosis; TLR = target lesion revascularization. Ellis S, et al. JACC Cardiovasc Interv. 2009;2:1248-1259. P values not significant except for TLR: Diabetes vs no diabetes, P < 0.05 TAXUS vs BMS, P <0.05 P values not significant except for TLR: Diabetes vs no diabetes, P < 0.05 TAXUS vs BMS, P <0.05

19. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 SYNTAX Diabetic Subgroup Analysis: Impact of Diabetes on CABG and Stenting Outcomes – Study Design Aspirin recommended indefinitely; thienopyridine for ≥6 monthsAspirin recommended indefinitely; thienopyridine for ≥6 months 1800 patients with left main disease and/or 1-, 2-, or 3-vessel disease 1800 patients with left main disease and/or 1-, 2-, or 3-vessel disease Stratified by the presence or absence of medically treated diabetes and left main disease Stratified by the presence or absence of medically treated diabetes and left main disease Diabetes (n = 452) Diabetes No diabetes (n = 1348) No diabetes (n = 1348) CABG (n = 676) CABG TAXUS ® DES (n = 672) CABG (n = 221) CABG TAXUS ® DES (n = 231) CABG = coronary artery bypass graft. Mack M, et al. Ann Thorac Surg. 2011 Dec;92(6):2140-6.

20. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 SYNTAX Diabetic Subgroup Analysis: Diabetes Increased Adverse Outcomes More in Patients Receiving TAXUS ® DES vs CABG Outcomes at 3 Years in Patients With vs Without Diabetes P = 0.633 P < 0.001 P = 0.505 P = 0.102 P < 0.001 P = 0.345 P = 0.087 P < 0.001 Patients, % CABG = coronary artery bypass graft. Mack M, et al. Ann Thorac Surg. Dec;92(6):2140-6.

21. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 ENDEAVOR IV Diabetic Analysis: Impact of Diabetes on Treatment With Endeavor ® ZES vs TAXUS ® PES in Patients With Diabetes – Study Design Primary endpoint was the rate of target vessel failure, a composite of cardiac death, myocardial infarction, or clinically driven target vessel revascularizationPrimary endpoint was the rate of target vessel failure, a composite of cardiac death, myocardial infarction, or clinically driven target vessel revascularization Drug therapy: aspirin and clopidogrel/ticlopidine for ≥6 monthsDrug therapy: aspirin and clopidogrel/ticlopidine for ≥6 months 1548 patients with single de novo native coronary artery lesions RVD, ≥2.5-≤3.5 mm; lesion length, ≤27 mm 1548 patients with single de novo native coronary artery lesions RVD, ≥2.5-≤3.5 mm; lesion length, ≤27 mm 80 US sites Stratified by diabetic status and clinical site 80 US sites Stratified by diabetic status and clinical site No diabetes (n = 1071) No diabetes (n = 1071) Diabetes (n = 477) Diabetes Endeavor ZES (n = 241) TAXUS PES (n = 236) Endeavor ZES (n = 532) TAXUS PES (n = 539) PES = paclitaxel-eluting stent; RVD = reference vessel diameter; ZES = zotarolimus-eluting stent. Kirtane A, et al. JACC Cardiovasc Interv. 2009;2:967-976.

22. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 ENDEAVOR IV Diabetic Analysis: Similar Outcomes at 1-Year in Patients With Diabetes Treated With E-ZES or PES P = 0.24 P = 1.00 P = 0.45 P = 0.19 P = 0.70 P = 0.87 P = 0.53 P = 0.89 P = 0.43 P = 0.62 P = 0.06 Outcomes and Major Adverse Events at 1 Year in Patients With vs Without Diabetes Incidence, % PES = paclitaxel-eluting stent; ST = stent thrombosis; TLR = target lesion revascularization; TVF = target vessel failure; TVR = target vessel revascularization; E-ZES = Endeavor zotarolimus-eluting stent. Kirtane A, et al. JACC Cardiovasc Interv. 2009;2:967-976.

23. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 SPIRIT IV Diabetic Cohort Analysis: Impact of Diabetes on Treatment With XIENCE V ® EES vs TAXUS ® PES – Study Design The primary endpoint was target lesion failure at 1 yearThe primary endpoint was target lesion failure at 1 year Aspirin ≥80 mg daily for 5 years; clopidogrel 75 mg daily for ≥12 months (if not at high risk for bleeding)Aspirin ≥80 mg daily for 5 years; clopidogrel 75 mg daily for ≥12 months (if not at high risk for bleeding) 3687 patients enrolled RVD, 2.5-3.75 mm; lesion length, ≤28 mm; ≤3 lesions with ≤2 per epicardial vessel ≤3 lesions with ≤2 per epicardial vessel 3687 patients enrolled RVD, 2.5-3.75 mm; lesion length, ≤28 mm; ≤3 lesions with ≤2 per epicardial vessel ≤3 lesions with ≤2 per epicardial vessel Randomized 2:1 XIENCE V ® EES:TAXUS Express ® PES Stratified by diabetes and presence of complex lesions; treatment predilatation mandatory Randomized 2:1 XIENCE V ® EES:TAXUS Express ® PES Stratified by diabetes and presence of complex lesions; treatment predilatation mandatory No diabetes (n = 2498) Diabetes (n = 1185) XIENCE V EES (n = 786) XIENCE V EES (n = 786) TAXUS PES (n = 399) XIENCE V EES (n = 1669) XIENCE V EES (n = 1669) TAXUS PES (n = 829) EES = everolimus-eluting stent; PES = paclitaxel-eluting stent; RVD = reference vessel diameter. Kereiakes D, et al. J Am Coll Cardiol. 2010;56:2084-2089. Clinical follow-up only: 1, 6, 9 months and yearly for 1-5 years

24. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 SPIRIT IV Diabetic Cohort Analysis: XIENCE V ® EES Did Not Significantly Impact Rates of TLF in Patients With Diabetes vs TAXUS ® PES TLF (Cardiac Death, TVMI, or Ischemia-Driven TLR), % 49/76126/37952/165255/815 RR (95% CI) = 0.47 (0.32-0.68); P = 0.80 RR (95% CI) = 0.94 (0.59-1.49); P < 0.001 P int = 0.02 Occurrence of Primary Endpoint: TLF at 1 Year RR = risk ratio; TLF = target lesion failure; TLR = target lesion revascularization; TVMI = target vessel myocardial infarction. Kereiakes D, et al. J Am Coll Cardiol. 2010;56:2084-2089.

25. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 SPIRIT/COMPARE Pooled Diabetic Analysis: Impact of Diabetes on Treatment With EES vs PES – Overview of Study Designs SPIRIT II SPIRIT III SPIRIT IV COMPARE Sites, n (location) 28 (EU, India, NZ) 65 (United States) 66 1(Netherlands) Intent-to-treat patients, n 300100236871800 Patients with diabetes, n (%) 69 (23.1) 290 (29.0) 1195 (32.4) 325 (18.1) EES:PES3:12:12:11:1 PES platform TAXUS ® Express ® TAXUS Liberté ® Primary endpoints In-stent LL at 6 months In-stent LL at 6 months; TVF at 9 months TLR at 12 months MACE at 12 months RVD, mm 2.5-4.252.5-3.752.5-3.75 Not specified Lesion length, mm ≤28 No limit EES = everolimus-eluting stent; EU = Europe; LL = late loss; MACE = major adverse cardiac event; NZ = New Zealand; PES = paclitaxel-eluting stent; RVD = reference vessel diameter; TLR = target lesion revascularization; TVF = target vessel failure. Stone G, et al. Circulation. 2011;124:893-900.

26. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 SPIRIT/COMPARE Pooled Diabetic Analysis: Patients Without Diabetes Treated With EES vs PES Had Significantly Reduced Outcomes EES vs PES: 2-Year Event Rates in Patients With vs Without Diabetes P < 0.0001 P = 0.88 P = 0.49 P = 0.10 P < 0.0001 P = 0.60 P = 0.50 P = 0.86 P < 0.0001 Patients, % EES = everolimus-eluting stent; MACE = major adverse cardiac event; PES = paclitaxel-eluting stent; ST = stent thrombosis. Stone G, et al. Circulation. 2011;124:893-900.

27. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 How Does the Resolute ™ ZES Perform in Diabetic Patients?

28. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 %Non-Diabetics N = 1903 Diabetics N = 878 Age (yr) 63.5 ± 10.8 65.2 ± 10.2 Male74.366.4 Diabetes mellitus 0100.0 IDDM IDDM028.5 Hypertension73.187.6 Hyperlipidemia76.086.2 Current smoker 22.118.2 Family history 42.237.8 Prior MI 25.524.9 Prior PCI 29.534.6 Prior CABG 7.410.5 Clinical status: Stable angina 45.546.2 Unstable angina 31.328.9 Myocardial infarction 6.65.4 Baseline Characteristics RESOLUTE Pooled Diabetic Analysis Pooled patient level data from RESOLUTE, R-AC, R-Int, R-US and R-Japan trials.

29. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 Target Lesion Failure to 2 Years RESOLUTE Pooled Diabetic Analysis 9.6% 7.1% 0 Time After Initial Procedure (months) Diabetics (N = 878) Cumulative Incidence of TLF 6121824 20% 15% 10% 0% 6.6% 4.9% Non-Diabetics (N = 1903) No. at risk Non-Diabetics19031870181617631714 Diabetics878873839800785 5% Target lesion failure (TLF) is defined as cardiac death, target vessel myocardial infarction and target lesion revascularization (TLR). Pooled patient level data from RESOLUTE, R-AC, R-Int, R-US and R-Japan trials. The RESOLUTE Pooled analysis was not specifically designed or powered for the analysis shown above.

30. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 RESOLUTE Pooled Diabetic Analysis TLRCardiac Death TVMI Stent Thrombosis TLF Clinical Outcomes at 24 Months Target vessel failure (TVF) is defined as cardiac death, target vessel MI, and clinically driven TVR. Target lesion failure (TLF) is defined as cardiac death, target vessel MI and TLR. TLR is clinically driven. Stent thrombosis is defined as definite or probable (Academic Research Consortium). Pooled patient level data from RESOLUTE, R-AC, R-Int, R-US and R-Japan trials. Resolute Pooled standard risk diabetic analysis was not specifically designed or powered for the endpoints other than TVF Events (%) RESOLUTE Pooled analysis, Standard risk diabetics (n=861/878) TVF

31. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 %Non-Diabetics N = 1903 Non-IDDM N = 628 IDDM N = 250 Age (yr) 63.5± 10.8 65.5 ± 10.3* 64.6 ± 10.0 Male74.370.456.4** Diabetes mellitus 0100.0*100.0 IDDM IDDM00100.0** Hypertension73.186.0*91.6** Hyperlipidemia76.086.0*86.8 Current smoker 22.118.617.2 Family history 42.237.638.4 Prior MI 25.525.722.9 Prior PCI 29.533.9*36.4 Prior CABG 7.411.1*8.8 Clinical status: * Stable angina 45.546.844.8 Unstable angina 31.328.530.0 Myocardial infarction 6.64.38.0 Baseline Characteristics RESOLUTE Pooled Diabetic Analysis *p-value <0.05 Non-IDDM vs. Non-Diabetics ** p-value <0.05 IDDM vs Non-IDDM

32. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 Target Lesion Revascularization to 2 Years RESOLUTE Pooled Diabetic Analysis 0 Time After Initial Procedure (months) Cumulative Incidence of Cardiac Death/TLR 6121824 20% 15% 10% 0% No. at risk Non-Diabetics19031900185918091763 Non-IDDM628627614589579 IDDM250250236222216 5% Non-Diabetics (N = 1903) 3.4% 2.1% 6.5% 4.3% 5.4% 2.6% Non-IDDM (N = 628) IDDM (N = 250) Pooled patient level data from RESOLUTE, R-AC, R-Int, R-US and R-Japan trials. The RESOLUTE Pooled analysis was not specifically designed or powered for the analysis shown above.

33. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 Cardiac Death/TVMI to 2 Years RESOLUTE Pooled Diabetic Analysis 4.1% 0 Time After Initial Procedure (months) Cumulative Incidence of Cardiac Death/TVMI 6121824 20% 15% 10% 0% 3.1% Non-Diabetics (N = 1903) No. at risk Non-Diabetics19031872183317961757 Non-IDDM628626613599593 IDDM250248232227222 5% Non-IDDM (N = 628) IDDM (N = 250) 8.6% 3.9% 6.0% 2.6% Pooled patient level data from RESOLUTE, R-AC, R-Int, R-US and R-Japan trials. The RESOLUTE Pooled analysis was not specifically designed or powered for the analysis shown above.

34. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 0.43% Stent Thrombosis to 2 Years RESOLUTE Pooled Diabetic Analysis 0 Time After Initial Procedure (months) Cumulative Incidence of ARC Def/Prob ST 6121824 10% 8% 6% 0% 4% Non-Diabetics (N = 1903) 2% No. at risk Non-Diabetics19031902187618421806 Non-IDDM628627617604598 IDDM250250240234229 0.32% 0.80% 0.16% 0.80% 0.16% Non-IDDM (N = 628) IDDM (N = 250) Stent thrombosis is definite or probable as defined by the Academic Research Consortium. Pooled patient level data from RESOLUTE, R-AC, R-Int, R-US and R-Japan trials. The RESOLUTE Pooled analysis was not specifically designed or powered for the analysis shown above.

35. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 RISICO Diabetic Analysis: Resolute ® ZES Appears to Be Highly Efficacious Even in Patients With Diabetes P = 0.760 P = 0.437 P = 0.943 P = 0.294 Outcomes in Patients With vs Without Diabetes Receiving Resolute ZES Incidence, % ZES = zotarolimus-eluting stent. Lelasi A, et al. Presented at: EuroPCR. 2011.

36. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 Summary (I) The prevalence of diabetes and cardiovascular disease is increasingThe prevalence of diabetes and cardiovascular disease is increasing The risk of serious adverse events is increased in patients with both diabetes and cardiovascular diseaseThe risk of serious adverse events is increased in patients with both diabetes and cardiovascular disease Percutaneous coronary intervention procedures in patients with diabetes result in inferior outcomesPercutaneous coronary intervention procedures in patients with diabetes result in inferior outcomes

37. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 Summary (II) Resolute Integrity™ is the only drug-eluting stent approved to treat patients with diabetes in the United StatesResolute Integrity™ is the only drug-eluting stent approved to treat patients with diabetes in the United States There is a lack of robust clinical evidence to support the use of most drug-eluting stents in patients with diabetesThere is a lack of robust clinical evidence to support the use of most drug-eluting stents in patients with diabetes The Resolute ™ stent showed consistently low event rates out to two years despite the higher risk nature of this diabetic patient population.The Resolute ™ stent showed consistently low event rates out to two years despite the higher risk nature of this diabetic patient population. The Resolute ™ stent showed that outcomes in patients with NIDDM appear to be similar to non- diabetic patients.The Resolute ™ stent showed that outcomes in patients with NIDDM appear to be similar to non- diabetic patients.

38. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 Indications The Resolute Integrity Zotarolimus-Eluting Coronary Stent System is indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length ≤ 27 mm in native coronary arteries with reference vessel diameters of 2.25 mm to 4.20 mm. Contraindications The Resolute Integrity Zotarolimus-Eluting Coronary Stent System is contraindicated for use in: Patients with a known hypersensitivity or allergies to aspirin, heparin, bivalirudin, clopidogrel, prasugrel, ticagrelor, ticlopidine, drugs such as zotarolimus, tacrolimus, sirolimus, everolimus or similar drugs or any other analogue or derivative Patients with a known hypersensitivity to the cobalt-based alloy (cobalt, nickel, chromium and molybdenum) Patients with a known hypersensitivity to the BioLinx® polymer or its individual components Coronary artery stenting is contraindicated for use in: Patients in whom antiplatelet and/or anticoagulation therapy is contraindicated Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the stent or stent delivery system Warnings Please ensure that the inner package has not been opened or damaged as this would indicate the sterile barrier has been breached. The use of this product carries the same risks associated with coronary artery stent implantation procedures, which include subacute and late vessel thrombosis, vascular complications and/or bleeding events. This product should not be used in patients who are not likely to comply with the recommended antiplatelet therapy. Precautions Only physicians who have received adequate training should perform implantation of the stent. Stent placement should only be performed at hospitals where emergency coronary artery bypass graft surgery can be readily performed. Subsequent stent restenosis or occlusion may require repeat catheter-based treatments (including balloon dilatation) of the arterial segment containing the stent. The long-term outcome following repeat catheter-based treatments of previously implanted endothelialized stents is not well characterized. The risks and benefits of the stent implantation should be assessed for patients with a history of severe reaction to contrast agents. Do not expose or wipe the product with organic solvents such as alcohol. When drug-eluting stents (DES) are used outside the specified Indications for Use, patient outcomes may differ from the results observed in the RESOLUTE pivotal clinical trials. Compared to use within the specified Indications for Use, the use of DES in patients and lesions outside of the labeled indications, including more tortuous anatomy, may have an increased risk of adverse events, including stent thrombosis, stent embolization, myocardial infarction (MI), or death Care should be taken to control the position of the guide catheter tip during stent delivery, deployment, and balloon withdrawal. Before withdrawing the stent delivery system, visually confirm complete balloon deflation by fluoroscopy to avoid guiding catheter movement into the vessel and subsequent arterial damage Stent thrombosis is a low- frequency event that is frequently associated with MI or death. Data from the RESOLUTE clinical trials have been prospectively evaluated and adjudicated using the definition developed by the Academic Research Consortium (ARC). The safety and effectiveness of the Resolute Integrity stent have not yet been established in the following patient populations: Patients with target lesions which were treated with prior brachytherapy or the use of brachytherapy to treat in-stent restenosis of a Resolute Integrity stent Women who are pregnant or lactating Men intending to father children Pediatric patients Patients with coronary artery reference vessel diameters of 4.20 mm Patients with coronary artery lesions longer than 27 mm or requiring more than one Resolute Integrity stent Patients with evidence of an acute MI within 72 hours of intended stent implantation Patients with vessel thrombus at the lesion site Patients with lesions located in a saphenous vein graft, in the left main coronary artery, ostial lesions, or bifurcation lesions Patients with diffuse disease or poor flow distal too identified lesions Patients with tortuous vessels in the region of the target vessel or proximal to the lesion Patients with in-stent restenosis Patients with moderate or severe lesion calcification at the target lesion Patients with occluded target lesions including chronic total occlusions Patients with three-vessel disease Patients with a left ventricular ejection fraction of 2.5mg/dl Patients with longer than 24 months of follow-up The safety and effectiveness of the Resolute Integrity stent have not been established in the cerebral, carotid or peripheral vasculature. Potential Adverse Events Other risks associated with using this device are those associated with percutaneous coronary diagnostic (including angiography and IVUS) and treatment procedures. These risks (in alphabetical order) may include but are not limited to: Abrupt vessel closure Access site pain, hematoma or hemorrhage Allergic reaction (to contrast, antiplatelet therapy, stent material, or drug and polymer coating) Aneurysm, pseudoaneurysm, or arteriovenous fistula (AVF) Arrhythmias, including ventricular fibrillation Balloon rupture Bleeding Cardiac tamponade Coronary artery occlusion, perforation, rupture or dissection Coronary artery spasm Death Embolism (air, tissue, device or thrombus) Emergency surgery: peripheral vascular or coronary bypass Failure to deliver the stent Hemorrhage requiring transfusion Hypotension/hypertension Incomplete stent apposition Infection or fever MI Pericarditis Peripheral ischemia/peripheral nerve injury Renal failure Restenosis of the stented artery Shock/pulmonary edema Stable or unstable angina Stent deformation, collapse, or fracture Stent migration (or embolization) Stent misplacement Stroke/transient ischemic attack Thrombosis (acute, subacute or late) Adverse Events Related to Zotarolimus Patients’ exposure to zotarolimus is directly related to the total amount of stent length implanted. The actual side effects/complications that may be associated with the use of zotarolimus are not fully known. The adverse events that have been associated with the intravenous injection of zotarolimus in humans include but are not limited to: Anemia Diarrhea Dry skin Headache Hematuria Infection Injection site reaction Pain (abdominal, arthralgia, injection site) Rash Please reference appropriate product Instructions for Use for more information regarding indications, warnings, precautions and potential adverse events. CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician. All brand names, product names or trademarks belong to their respective holders. Resolute ™ DES Safety Information

39. Trademarks may be registered and are the property of their respective owners. © 2012 Medtronic, Inc. All rights reserved. UC201303039EN 10/2012 Indications The Endeavor ® Sprint Zotarolimus-Eluting Coronary Stent Delivery System is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo lesions of length ≤27 mm in native coronary arteries with reference vessel diameters of ≥2.5 mm to ≤3.5 mm. Contraindications The Endeavor Zotarolimus-Eluting Coronary Stent System is contraindicated for use in: Patients with a known hypersensitivity to zotarolimus or structurally related compounds Patients with a known hypersensitivity to the cobalt-based alloy (cobalt, nickel, chromium, and molybdenum) Patients with a known hypersensitivity to Phosphorylcholine polymer or its individual components. Coronary artery stenting is contraindicated for use in: Patients with a known hypersensitivity or allergies to aspirin, heparin, clopidogrel or ticlopidine Patients who cannot receive recommended antiplatelet and/or anticoagulation therapy Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the stent or stent delivery system. Warnings Please ensure that the inner package has not been opened or damaged, as this indicates the sterile barrier has been breached The use of this product carries the risks associated with coronary artery stenting, including subacute thrombosis, vascular complications, and/ or bleeding events This product should not be used in patients who are not likely to comply with the recommended antiplatelet therapy. Precautions Only physicians who have received adequate training should perform implantation of the stent Stent placement should only be performed at hospitals where emergency coronary artery bypass graft surgery can be readily performed Subsequent stent blockage may require repeat dilatation of the arterial segment containing the stent. The long-term outcome following repeat dilatation of endothelialized stents is not well characterized Risks and benefits of the stent should be assessed for patients with history of severe reaction to contrast agents Do not expose or wipe the product with organic solvents such as alcohol or detergents Stent thrombosis is a low-frequency event that current drug-eluting stent (DES) clinical trials are not adequately powered to fully characterize. Stent thrombosis is frequently associated with myocardial infarction (MI) or death. Data from the ENDEAVOR randomized clinical trials have been prospectively evaluated and adjudicated using both the protocol definition of stent thrombosis and the definition developed by the Academic Research Consortium (ARC), and demonstrate specific patterns of stent thrombosis that vary depending on the definition used. In the ENDEAVOR clinical trials analyzed to date, the differences in the incidence of stent thrombosis observed with the Endeavor stent compared to bare metal stents have not been associated with an increased risk of cardiac death, MI, or allcause mortality. Additional data from longer-term follow-up in the ENDEAVOR randomized clinical trials and analyses of DES-related stent thrombosis are expected and should be considered in making treatment decisions as data become available When DES are used outside the specified Indications for Use, patient outcomes may differ from the results observed in the pivotal clinical trials Compared to use within the specified Indications for Use, the use of DES in patients and lesions outside of the labeled indications, including more tortuous anatomy, may have an increased risk of adverse events, including stent thrombosis, stent embolization, MI, or death. The safety and effectiveness of the Endeavor stent have not yet been established in the following patient populations: Women who are pregnant or lactating Men intending to father children Pediatric patients Patients with vessel thrombus at the lesion site Patients with coronary artery reference vessel diameters 3.5 mm Patients with coronary artery lesions longer than 27 mm or requiring more than one Endeavor stent Patients with lesions located in saphenous vein grafts, in the unprotected left main coronary artery, ostial lesions, or lesions located at a bifurcation Patients with diffuse disease or poor flow distal to the identified lesions Patients with multivessel disease Patients with tortuous vessels in the region of the obstruction or proximal to the lesion Patients with a recent acute myocardial infarction where there is evidence of thrombus or poor flow Patients for longer than 48 months of follow-up Patients with in-stent restenosis Patients with moderate or severe calcification in the lesion or a chronic total occlusion Patients with prior brachytherapy of the target lesion or the use of brachytherapy to treat in-stent restenosis in an Endeavor stent. The safety and effectiveness of the Endeavor stent have not been established in the cerebral, carotid, or peripheral vasculature. Potential Adverse Events Other risks associated with using this device are those associated with percutaneous coronary diagnostic (including angiography and IVUS) and treatment procedures. These risks may include, but are not limited to Abrupt vessel closure Access site pain, hematoma or hemorrhage Allergic reaction (to contrast, antiplatelet therapy, stent material, or drug and polymer coating) Aneurysm, pseudoaneurysm, or arteriovenous fistula (AVF) Arrhythmias Balloon rupture Cardiac tamponade Coronary artery occlusion, perforation, rupture, or dissection Coronary artery spasm Death Embolism (air, tissue, device, or thrombus) Emergency surgery: peripheral vascular or coronary bypass Failure to deliver the stent Hemorrhage requiring transfusion Hypotension/hypertension Incomplete stent apposition Infection or fever Late or very late thrombosis Myocardial infarction (MI) Myocardial ischemia Peripheral ischemia/peripheral nerve injury Renal failure Restenosis of the stented artery Rupture of native or bypass graft Shock/pulmonary edema Stent deformation, collapse, or fracture Stent migration Stent misplacement Stroke/transient ischemic attack Thrombosis (acute and subacute) Unstable angina Ventricular fibrillation. Adverse Events Related to Zotarolimus Patients’ exposure to zotarolimus is directly related to the total amount of stent length implanted. The actual side effects/complications that may be associated with the use of zotarolimus are not fully known. The adverse events that have been associated with the intravenous injection of zotarolimus in humans include Anemia Application site reaction Diarrhea Dry skin Headache Hematuria Infection Injection site reaction Pain (abdominal, arthralgia, injection site) Rash. Please reference appropriate product Instructions for Use for more information regarding indications, warnings, precautions and potential adverse events. CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician. All brand names, product names or trademarks belong to their respective holders. Endeavor DES Safety Information